 Travere Therapeutics Inc NASDAQ: TVTX has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis FSGS. See: Travere Therapeutics Sparsentan Program Submission Pushed to 2022; FDA Requires More Data. 